TD Cowen keeps a Buy rating on Sangamo (SGMO) after Pfizer (PFE) decided to terminate the global collaboration and license agreement between the parties. Sangamo will regain full rights to to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of adults with moderately severe to severe hemophilia A, in April, but will not receive a “critical” anticipated milestone payment nor a breakup fee, the analyst tells investors in a research note. TD is “disappointed” in Pfizer’s decision, which it says is likely driven by the limited commercial success of BioMarin’s (BMRN) Roctavian. TD awaits additional information from Sangamo on a strategy to shore up its cash runway,
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMO:
- Penny Stock Sangamo (SGMO) Nosedives as Pfizer Terminates Partnership
- Sangamo decline on Pfizer collaboration decision ‘overdone’, says Barclays
- Closing Bell Movers: CompoSecure gains 5% on Resolute Holdings spinoff
- Sangamo Biosciences Faces Pfizer Collaboration Termination
- Sangamo down 31% at $1.61 after Pfizer decision to terminate collaboration
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue